Autologous means the tissue goes back to the person it came from. Allogeneic means it goes to someone else. In adipose banking that one distinction decides which federal pathway applies, which donor screening rules attach, and what must be printed on the label. Nothing adipose-derived is FDA approved for any disease.
TLDR Autologous means tissue goes back to its own donor. Allogeneic means it goes to another person. The distinction is written into 21 CFR 1271.10(a)(4)(ii), which also names first-degree and second-degree blood relatives as a regulatory pathway criterion, not a promise of access. Autologous material is excepted from donor screening and testing at 1271.90, and must be labeled accordingly. Banking guarantees no eligibility, access, or clinical benefit.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently has FDA approval for any disease, autologous or allogeneic. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
Two words appear on consent forms, product labels, and trial registries, usually without explanation. Most readers scan past them as jargon. They describe who the tissue came from and who it is for.
FDA regulates human cells, tissues, and cellular and tissue-based products under Part 1271. Inside that part, a short set of criteria decides whether a product stays under Section 361 or moves into the drug and biologic pathway. The last one names the donor relationship outright.
Readers new to the subject can start with adipose tissue banking or how banking works, then return to the donor question, where the confusion lives.
What Autologous and Allogeneic Mean in FDA’s Rules
Autologous means the donor and the recipient are the same person. Allogeneic means they are two different people. Neither word says anything about approval, and the difference shows up in the fourth of the four criteria at 21 CFR 1271.10(a).
A product sits under Section 361 only when it meets all four. The first three cover manipulation, homologous use, and combination with other articles.
The fourth criterion splits. Either the product has no systemic effect and does not depend on the metabolic activity of living cells for its primary function, or it does and is for autologous use, for allogeneic use in a first-degree or second-degree blood relative, or for reproductive use. Anything failing 1271.10(a) is regulated under 1271.20 as a drug, device, or biological product.
The Blood Relative Clause at 21 CFR 1271.10(a)(4)(ii)
Federal regulation does name blood relatives. It does not hand them access to anything. The clause is one prong of one criterion, and it decides which pathway a product travels, not who may receive it.
Read in place, it says a product with a systemic effect, or one dependent on the metabolic activity of living cells, can still sit under Section 361 when it is for autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use.
What it does not do matters more. It creates no product, no approval, and no right of access. Eligibility for any therapy is set by that therapy and its sponsor, not by a family tie, and banking guarantees no eligibility, access, or clinical benefit for anyone, related or not.
There is a practical collision too. A sample stored for autologous use is labeled that way, and one excepted from screening was never evaluated with a second recipient in mind. Family eligibility goes further.
What Screening and Testing Changes Between the Two
Nearly everything. For a person’s own tissue, the federal donor-eligibility determination and its testing requirements do not apply. For allogeneic material, they do.
Subpart C requires a donor eligibility determination for all donors except as provided under 1271.90. The autologous exception at 21 CFR 1271.90(a)(1) reads: “You are not required to make a donor-eligibility determination under 1271.50 or to perform donor screening or testing under 1271.75, 1271.80 and 1271.85 for: (1) Cells and tissues for autologous use”.
Allogeneic material receives no such exception. Screening categories cover HIV, hepatitis B, hepatitis C, human transmissible spongiform encephalopathy including Creutzfeldt-Jakob disease, and Treponema pallidum. Required testing adds HIV type 1, HIV type 2, hepatitis B virus, hepatitis C virus, and Treponema pallidum, plus HTLV-I, HTLV-II, and CMV for viable leukocyte-rich material, and that testing must be done by a CLIA-certified laboratory or equivalent.
What the Label Must Say in Adipose Banking
Two strings, both from the same rule. Under 21 CFR 1271.90(c), material stored for autologous use must be labeled “FOR AUTOLOGOUS USE ONLY,” and must also carry “NOT EVALUATED FOR INFECTIOUS SUBSTANCES” unless the screening and testing were performed anyway.
The second string is the honest consequence of the first. An exception from testing is not a finding that a sample is free of infectious agents, and the label says so in capital letters.
Read the scope precisely. The exception reaches donor eligibility screening and testing, and nothing else. It is not an exception to registration, listing, current good tissue practice, labeling, or the 1271.10(a) criteria, and FDA adipose regulations set out the wider framework.
Which Approved Products Are Allogeneic
The only FDA-approved mesenchymal stromal cell product is allogeneic, and it is not adipose. RYONCIL (remestemcel-L-rknd), from Mesoblast, was approved in December 2024 for steroid-refractory acute graft-versus-host disease in pediatric patients 2 months and older.
The FDA announcement and the package insert describe cells “isolated from the bone marrow of healthy human adult donors,” so it does not validate adipose banking. FDA-licensed cord blood products are allogeneic too, and FDA’s consumer alert says the only approved stem cell products are blood-forming stem cells from umbilical cord blood, for disorders of blood production only.
Adipose research runs on both tracks at once, and one sponsor often runs each. The four registry records below were verified on ClinicalTrials.gov.
| Study record | Sponsor | Donor relationship | Phase and status | Condition studied |
|---|---|---|---|---|
| NCT05951777 | Hope Biosciences LLC | Autologous | Phase 2, recruiting | Traumatic brain injury |
| NCT06654193 | Hope Biosciences LLC | Allogeneic | Phase 1/2, recruiting | Acute kidney injury |
| NCT04520373 | Mayo Clinic | Autologous | Phase 2, active not recruiting | Spinal cord injury |
| NCT05789394 | Mayo Clinic | Allogeneic | Phase 1, recruiting | Recurrent glioblastoma |
Recruiting means enrolling, not effective, and none of these is FDA approved. This science is preliminary and early stage, so only a licensed provider can judge relevance for one person.
Frequently Asked Questions
Does banking a person’s own tissue mean a family member could use it?
No. The regulation names first-degree and second-degree blood relatives inside one criterion at 1271.10(a), and that criterion decides a product’s regulatory pathway. It is not an access right or a promise. Banking guarantees no eligibility, access, or clinical benefit for anyone, related or not.
Is autologous material safer than allogeneic material?
The regulation does not rank them by safety. Allogeneic material carries the full screening and testing load, while autologous material is excepted and must be labeled “NOT EVALUATED FOR INFECTIOUS SUBSTANCES” when that work was not performed. Absence of testing is not a finding of safety.
Is any autologous or allogeneic adipose product FDA approved?
No. FDA’s roster of approved cellular therapies lists no adipose-derived product for any disease. Work under study is preliminary and early stage, and only a licensed provider can advise an individual.
Key Takeaways
Autologous and allogeneic describe who the tissue came from and who it is for. The relationship is written into 21 CFR 1271.10(a), where the fourth criterion allows autologous use, allogeneic use in a first-degree or second-degree blood relative, or reproductive use. That blood-relative clause is a pathway criterion, not an access right. Autologous material is excepted from donor screening and testing under 1271.90 and must be labeled for autologous use only. Allogeneic material carries the full load. No adipose-derived product is FDA approved.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Readers weighing adipose tissue banking for potential future use can compare current pricing or ask a question through the contact page.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about adipose tissue banking or research participation.
About the author: Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent more than a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.
Related guide: FDA adipose tissue regulation.
